Skip to main content
. 2023 Dec 29;67(1):81–109. doi: 10.1021/acs.jmedchem.3c00925

Table 2. In Vitro Antimycobacterial Activities of the Final Tetrazole-Based Compounds of Series 52–56 Expressed as MIC (μM) and Their Comparison with Those of Parent Tetrazoles 1a–e12.

graphic file with name jm3c00925_0013.jpg

  X M. tuberculosis My 331/88a M. avium My 330/88a M. kansasii My 235/80b
INH   0.5/1 250/250 250/250/250
pretomanid   0.125/0.25 >32/>32 >32/>32/>32
1a NO2 4/4 62/62 2/4/16
1b NO2 2/4 16/32 1/4/4
1c NO2 1/2 125/125 2/4/4
1d NO2 1/1 125/125 1/2/2
1e NO2 1/1 16/32 4/4/4
52a CF3 32/64 250/250 125/250/250
52b CF3 32/64 250/250 125/250/250
52c CF3 32/32 250/250 125/250/250
52d CF3 64/125 250/250 125/250/250
52e CF3 64/64 250/250 64/64/64
53a Cl 64/125 250/250 125/250/250
53b Cl 250/250 250/250 125/250/250
53c Cl 250/250 250/250 250/250/250
53d Cl 250/250 250/250 125/250/250
53e Cl 250/250 250/250 125/250/250
54a F 250/250 250/250 125/250/250
54b F 250/250 250/250 125/250/250
54c F 125/250 250/250 125/250/250
54d F 64/64 250/250 64/125/250
54e F 64/125 250/250 125/250/250
55a–55e Br >250 >250 >250
56a CN 250/250 250/250 250/250/250
56b CN 32/32 250/250 16/32/32
56c CN 2/4 250/250 4/8/16
56d CN 32/32 250/250 16/32/32
56e CN 250/250 250/250 250/250/250
a

14/21 days.

b

7/14/21 days.